

Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside <i>D. L. Bhatt</i>	J1
Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites <i>T. D. O'Connell, R. P. Mason, M. J. Budoff, A. M. Navar and G. C. Shearer</i>	J3
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap <i>K. G. Parhofer, M. J. Chapman and B. G. Nordestgaard</i>	J21
Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies <i>B. Olshansky, M. K. Chung, M. J. Budoff, S. Philip, L. Jiao, R. T. Doyle, Jr., C. Copland, A. Giaquinto, R. A. Juliano and D. L. Bhatt</i>	J34
The journey of omega-3 fatty acids in cardiovascular medicine <i>R. Ferrari, S. Censi and P. Cimaglia</i>	J49
Beyond cardiovascular medicine: potential future uses of icosapent ethyl <i>D. L. Bhatt, M. A. Hull, M. Song, C. Van Hulle, C. Carlsson, M. J. Chapman and P. P. Toth</i>	J54